Sara Sheikhbahaei1, Mehdi Taghipour1, Rubina Ahmad1, Carole Fakhry2,3, Ana P Kiess4, Christine H Chung5, Rathan M Subramaniam1,2,5,6. 1. 1 Russell H. Morgan Department of Radiology and Radiological Sciences, Johns Hopkins University School of Medicine, 601 N Caroline St, JHOC 3235, Baltimore, MD 21287. 2. 2 Department of Otolaryngology and Head and Neck Surgery, Johns Hopkins University School of Medicine, Baltimore, MD. 3. 3 Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD. 4. 4 Department of Radiation Oncology and Radiation Molecular Sciences, Johns Hopkins University School of Medicine, Baltimore, MD. 5. 5 Department of Medical Oncology, Johns Hopkins University School of Medicine, Baltimore, MD. 6. 6 Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Abstract
OBJECTIVE: The purpose of this study was to assess the diagnostic performance of FDG PET or PET/CT for detection of local, regional, and distant recurrences in the follow-up of patients with head and neck cancer who underwent definitive treatment. MATERIALS AND METHODS: A systematic search was performed in MEDLINE and Cochrane Library (updated September 2014) to identify relevant published studies. Studies investigating the accuracy of FDG PET/CT that were performed at least 4 months after therapy were included. Two authors independently screened all retrieved articles, selected studies that met the inclusion criteria, and extracted the data. Histopathologic confirmation or clinical follow-up of at least 6 month (or both) was considered as the reference standard. RESULTS: Twenty-three studies constituting a total of 2247 FDG PET/CT examinations met our inclusion criteria. The pooled sensitivity and specificity of follow-up PET/CT for detection of recurrence were 0.92 (95% CI, 0.90-0.94), and 0.87 (95% CI, 0.82-0.91), respectively. The pooled sensitivity and specificity of scans performed 4-12 months after treatment were 0.95 (95% CI, 0.91-0.97) and 0.78 (95% CI, 0.70-0.84), respectively. Similar estimates for scans performed at or more than 12 months after treatment were 0.92 (95% CI, 0.85-0.96) and 0.91 (95% CI, 0.78-0.96), respectively. The overall accuracy of FDG PET/CT in detecting recurrence is higher in patients without suspicion of recurrence before the scan compared with the patients with suspected recurrence. CONCLUSION: The high diagnostic performance of FDG PET/CT in detecting recurrence in curatively treated patients with head and neck cancer supports its use in clinical practice for patient follow-up. Further studies are needed to evaluate the prognostic utility of PET/CT in the follow-up of head and neck cancer.
OBJECTIVE: The purpose of this study was to assess the diagnostic performance of FDG PET or PET/CT for detection of local, regional, and distant recurrences in the follow-up of patients with head and neck cancer who underwent definitive treatment. MATERIALS AND METHODS: A systematic search was performed in MEDLINE and Cochrane Library (updated September 2014) to identify relevant published studies. Studies investigating the accuracy of FDG PET/CT that were performed at least 4 months after therapy were included. Two authors independently screened all retrieved articles, selected studies that met the inclusion criteria, and extracted the data. Histopathologic confirmation or clinical follow-up of at least 6 month (or both) was considered as the reference standard. RESULTS: Twenty-three studies constituting a total of 2247 FDG PET/CT examinations met our inclusion criteria. The pooled sensitivity and specificity of follow-up PET/CT for detection of recurrence were 0.92 (95% CI, 0.90-0.94), and 0.87 (95% CI, 0.82-0.91), respectively. The pooled sensitivity and specificity of scans performed 4-12 months after treatment were 0.95 (95% CI, 0.91-0.97) and 0.78 (95% CI, 0.70-0.84), respectively. Similar estimates for scans performed at or more than 12 months after treatment were 0.92 (95% CI, 0.85-0.96) and 0.91 (95% CI, 0.78-0.96), respectively. The overall accuracy of FDG PET/CT in detecting recurrence is higher in patients without suspicion of recurrence before the scan compared with the patients with suspected recurrence. CONCLUSION: The high diagnostic performance of FDG PET/CT in detecting recurrence in curatively treated patients with head and neck cancer supports its use in clinical practice for patient follow-up. Further studies are needed to evaluate the prognostic utility of PET/CT in the follow-up of head and neck cancer.
Entities:
Keywords:
FDG PET; PET/CT; follow-up; head and neck neoplasm; meta-analysis; recurrence; sensitivity and specificity
Authors: Louise Madeleine Risør; Annika Loft; Anne Kiil Berthelsen; Frederik Cornelius Loft; Andreas Ruhvald Madsen; Ivan Richter Vogelius; Andreas Kjær; Jeppe Friborg Journal: Eur Arch Otorhinolaryngol Date: 2019-10-23 Impact factor: 2.503
Authors: Minerva Becker; Arthur D Varoquaux; Christophe Combescure; Olivier Rager; Marc Pusztaszeri; Karim Burkhardt; Bénédicte M A Delattre; Pavel Dulguerov; Nicolas Dulguerov; Eirini Katirtzidou; Francesca Caparrotti; Osman Ratib; Habib Zaidi; Christoph D Becker Journal: Eur Radiol Date: 2017-08-15 Impact factor: 5.315
Authors: Rens M G E van de Goor; Joey C A Hardy; Michel R A van Hooren; Bernd Kremer; Kenneth W Kross Journal: Head Neck Date: 2019-04-23 Impact factor: 3.147
Authors: S Connor; C Sit; M Anjari; M Lei; T Guerrero-Urbano; T Szyszko; G Cook; P Bassett; V Goh Journal: J Cancer Res Clin Oncol Date: 2021-06-22 Impact factor: 4.553
Authors: Renata Fockink Dos Anjos; Dalton Alexandre Dos Anjos; Danielle Leal Vieira; André Ferreira Leite; Paulo Tadeu de Souza Figueiredo; Nilce Santos de Melo Journal: Medicine (Baltimore) Date: 2016-08 Impact factor: 1.889